时间高效型前列腺癌治疗的成本与并发症:国家医保数据分析
基于2011至2014年美国国家医保索赔数据,比较前列腺切除术、近距离放疗、立体定向体部放疗(SBRT)与主动监测(AS)在新诊断前列腺癌中的1年成本和毒性。SBRT平均1年调整成本最高(26895美元),近距离放疗最低(19980美元),AS为9687美元;前列腺切除术泌尿失禁和性功能障碍风险最高,放疗模式泌尿刺激/出血和胃肠溃疡/狭窄/瘘风险较高。
要点
- SBRT平均1年调整成本最高(26895美元),近距离放疗最低(19980美元),AS为9687美元。
- 前列腺切除术泌尿失禁HR=10.8、性功能障碍HR=3.5(对比AS)。
- 近距离放疗泌尿刺激/出血HR=1.7、胃肠溃疡/狭窄/瘘HR=2.7;SBRT对应HR=1.5和3.0。
核心结论
- 时间高效型前列腺癌治疗技术在毒性和成本上存在显著差异,地理区域显著影响治疗成本。
研究设计与样本
- 识别前列腺切除术、近距离放疗和SBRT三个根治性治疗队列,并通过倾向评分逆概率治疗加权匹配主动监测队列。
- 计算活检后1年总成本,并通过各根治治疗组1年总成本减去AS组1年总成本估算治疗特异性成本。
主要发现
- 平均1年调整成本SBRT最高(26895美元),前列腺切除术次之(23632美元),近距离放疗最低(19980美元),AS为9687美元。
- 根治性治疗成本区域差异显著,中大西洋和新英格兰地区成本范围最高(>10000美元),西南中部和山区最低(<2000美元)。
- 前列腺切除术与较高的泌尿失禁(HR=10.8,对比AS)和性功能障碍(HR=3.5)相关。
- 放疗模式与较高的泌尿刺激/出血(近距离放疗HR=1.7;SBRT HR=1.5)和胃肠溃疡/狭窄/瘘(近距离放疗HR=2.7;SBRT HR=3.0)相关。
- 总体平均毒性成本前列腺切除术最高(3500美元),其次为近距离放疗(1847美元)、SBRT(1327美元)和AS(1303美元)。
临床怎么用
- 临床决策应综合考虑时间高效型治疗的毒性差异和成本,前列腺切除术泌尿失禁和性功能障碍风险较高,放疗模式泌尿刺激/出血和胃肠溃疡/狭窄/瘘风险较高。
- 地理区域显著影响治疗成本,资源规划需考虑区域差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recent trends in payer and patient preferences increasingly incentivize time-efficient (≤2-week treatment time) prostate cancer treatments. METHODS AND MATERIALS: National Medicare claims from January 1, 2011, through December 31, 2014, were analyzed to identify newly diagnosed prostate cancers. Three "radical treatment" cohorts were identified (prostatectomy, brachytherapy, and stereotactic body radiation therapy [SBRT]) and matched to an active surveillance (AS) cohort by using inverse probability treatment weighting via propensity score. Total costs at 1 year after biopsy were calculated for each cohort, and treatment-specific costs were estimated by subtracting total 1-year costs in each radical treatment group from those in the AS group. RESULTS: Mean 1-year adjusted costs were highest among patients receiving SBRT ($26,895), lower for prostatectomy ($23,632), and lowest for brachytherapy ($19,980), whereas those for AS were $9687. Costs of radical modalities varied significantly by region, with the Mid-Atlantic and New England regions having the highest cost ranges (>$10,000) and the West South Central and Mountain regions the lowest range in costs (<$2000). Quantification of toxic effects showed that prostatectomy was associated with higher genitourinary incontinence (hazard ratio [HR] = 10.8 compared with AS) and sexual dysfunction (HR = 3.5), whereas the radiation modalities were associated with higher genitourinary irritation/bleeding (brachytherapy HR = 1.7; SBRT HR = 1.5) and gastrointestinal ulcer/stricture/fistula (brachytherapy HR = 2.7; SBRT HR = 3.0). Overall mean toxicity costs were highest among patients treated with prostatectomy ($3500) followed by brachytherapy ($1847), SBRT ($1327), and AS ($1303). CONCLUSIONS: Time-efficient treatment techniques exhibit substantial variability in toxicity and costs. Furthermore, geographic location substantially influenced treatment costs.
引用
- Tang C, Lei X, Smith GL, et al. Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. Pract Radiat Oncol. 2020. PMID: 32298794. doi:10.1016/j.prro.2020.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。